Skip to main content

LISATA THERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

LSTA$1.02-8.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets at December 31, 2025 and 2024

(In thousands, except share data)

December 31,2025December 31,2024
ASSETS
Current Assets
Cash and cash equivalents$15,956$16,209
Marketable securities—15,036
Accounts receivable—900
Prepaid and other current assets1,7472,433
Total current assets17,70334,578
Property and equipment, net1872
Acquired license-intangible, net—192
Other assets23160
Total assets$17,744$35,002
LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY
Liabilities
Accounts payable$1,019$1,284
Accrued liabilities2,0524,329
Total current liabilities3,0715,613
Other long-term liabilities7272
Total liabilities3,1435,685
Commitments and Contingencies (Note 14)
Stockholders' Equity
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,834,613 and 8,409,582 shares, at December 31, 2025 and December 31, 2024, respectively; and outstanding, 8,833,875 and 8,408,844 shares, at December 31, 2025 and December 31, 2024, respectively98
Additional paid-in capital580,243578,418
Treasury stock, at cost; 738 shares at December 31, 2025 and December 31, 2024 respectively(708)(708)
Accumulated deficit(564,652)(548,066)
Accumulated other comprehensive loss(37)(81)
Total Lisata Therapeutics, Inc. stockholders' equity14,85529,571
Non-controlling interests(254)(254)
Total equity14,60129,317
Total liabilities, non-controlling interests and stockholders' equity$17,744$35,002
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.